hero image

A statement from Biogen on LEQEMBI™ pricing

January 6, 2023 Company Statements

Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBITM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety is available on Eisai’s website.

A separate news release from Eisai on LEQEMBI pricing is also available via their website.  Eisai is solely responsible for setting LEQEMBI’s price.

thumb
April 24, 2024
BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2024 financial results Wednesday, April 24, 2024, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

thumb
March 31, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

TOKYO and CAMBRIDGE, Mass., April 1, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai submitted to the U.S.